Estrogen Monotherapy for Testosterone Suppression in Gender Diverse Patients

The study investigates the effectiveness of estrogen monotherapy in suppressing testosterone levels in gender diverse individuals assigned male at birth, specifically transfeminine patients. Conducted as a retrospective chart review, it included 10 patients aged 19-81, with 7 identifying as transfeminine. The results showed that 100% of these transfeminine patients achieved testosterone suppression with serum estradiol levels above 100 pg/mL, using either injectable or transdermal estrogen formulations. The study suggests that estrogen monotherapy could be a viable alternative to anti-androgen medications, though it acknowledges the limitation of a small sample size and calls for further research.